<ѻýҕl>Study Raises Questions on Nuedexta Prescribingѻýҕl> Real-world data show PBA drug given mainly to dementia and Parkinson's disease patients Jan 07, 2019
<ѻýҕl>Machine Learning Allows for Low-Dose Gadolinium Contrastѻýҕl> Minimal loss of resolution with 10% Gd dose Nov 30, 2018
<ѻýҕl>New Multiple Sclerosis Subtype Proposedѻýҕl> Finding may open new research targets Aug 23, 2018
<ѻýҕl>Elephants and Alzheimer's; Omega-3 and Epilepsy; Eye Disease and Dementiaѻýҕl> News and commentary from the world of neurology and neuroscience Aug 14, 2018
<ѻýҕl>Calif. Medical Board Acts on Doc With Risky MS 'Cure'ѻýҕl> Physician featured in States of Disgrace series Jul 31, 2018
<ѻýҕl>Some Multiple Sclerosis Agents May be Safe During Pregnancyѻýҕl> Stopping treatment may put MS patients at unnecessary risk Jun 05, 2018
<ѻýҕl>Still No Clarity on Role of Vitamin D in MS Relapseѻýҕl> But findings do help estimate needed sample size for a future prospective study Jun 04, 2018
<ѻýҕl>MRI Improvements in MS with Switch from IFN to Ocrelizumabѻýҕl> Rapid and robust reduction in activity Jun 04, 2018
<ѻýҕl>When Is the Ideal Time for Some MS Patients to Start DMT?ѻýҕl> Unclear benefits with disease-modifying therapies in older patients, asymptomatic patients Jun 03, 2018
<ѻýҕl>Twice-a-Week IFN Dose an Option in Breakthrough MSѻýҕl> Nearly two decades of data showed good outcomes Jun 02, 2018
<ѻýҕl>Biologic for MS Linked to Reduced Vaccine Responseѻýҕl> Ocrelizumab treatment associated with decreased humoral response Jun 01, 2018
<ѻýҕl>AAN 2018: Rare Disease Breakthroughs and Novel Approachesѻýҕl> Noteworthy presentations at American Academy of Neurology meeting Apr 20, 2018
<ѻýҕl>Docs, Medical Boards Ignored FDA Warning Letters on CCSVIѻýҕl> Fueled by YouTube, bogus MS 'cure' peddled by docs licensed in multiple states Mar 28, 2018
<ѻýҕl>Coffee and Cannabis; Stephen Hawking’s ALS; New Stroke Risk Lociѻýҕl> News and commentary from the world of neurology and neuroscience Mar 20, 2018
<ѻýҕl>NeuroBreak: Hits, Not Concussions, Cause CTE; Smoking and PD; APOE4 Newsѻýҕl> News and commentary from the world of neurology and neuroscience Jan 23, 2018
<ѻýҕl>Zamboni Stands By CCSVI Theory of MSѻýҕl> His own RCT turns up negative, but he vows to fight on as MS community moves on Dec 26, 2017
<ѻýҕl>New Immunoglobulin May Tell of MS Disease Severityѻýҕl> Preliminary study implicates IgA in MS disease activity for first time Nov 15, 2017
<ѻýҕl>Protein May Be Marker of MS Disease Severity, Remyelinationѻýҕl> Early work suggests beneficial effect of IL4I1 in multiple sclerosis Nov 13, 2017
<ѻýҕl>Anti-Inflammatory Drug May Offer Benefit in Progressive MSѻýҕl> Ibudilast seems to diminish brain volume loss Oct 29, 2017
<ѻýҕl>Strike Three for Laquinimod in Relapsing MSѻýҕl> Switching endpoints for third phase III trial didn't help Oct 27, 2017
<ѻýҕl>Getting a Handle on Benign MSѻýҕl> Prevalence varies by definition; agreed that disease progression varies widely Oct 27, 2017
<ѻýҕl>Vaccines Tied to Relapses in Neuromyelitis Opticaѻýҕl> Retrospective review finds protective factor in immunotherapy Oct 26, 2017
<ѻýҕl>Revised McDonald Diagnostic Criteria Revealedѻýҕl> Recommends using OCBs, both symptomatic and asymptomatic lesions to diagnose MS Oct 26, 2017
<ѻýҕl>FDA Panel Backs New Warning for Gadolinium Contrast Agentsѻýҕl> Manufacturers could be required to conduct new studies Sep 11, 2017
<ѻýҕl>Lymphoma Case Reported in MS Patient on Aubagioѻýҕl> First case in medical literature, more found in global surveillance reports Jul 07, 2017
<ѻýҕl>PPAR-Gamma Drug May Work in MSѻýҕl> In phase II study, drug diminished inflammatory lesions & cortical atrophy May 30, 2017
<ѻýҕl>McDonald Criteria for MS May Incorporate CSF Testingѻýҕl> Revision committee finds OCB testing may be useful in specific cases May 25, 2017
<ѻýҕl>NEPAD: Better Endpoint for Progressive MS Trials?ѻýҕl> Tweak to 'no evidence of disease activity' standard stiffens criteria for progression May 02, 2017
<ѻýҕl>New Hints that Vitamin D Helps MS Patientsѻýҕl> Two randomized trials miss endpoints but still strongly suggest benefit Apr 28, 2017
<ѻýҕl>Is 'No Evidence of Disease Activity' a Misnomer in MS?ѻýҕl> Many patients still show signs of active disease despite meeting current NEDA criteria Apr 25, 2017
<ѻýҕl>'This is a Quadfecta!' What We Heard This Weekѻýҕl> Quotable quotes from ѻýҕl's sources Mar 31, 2017
<ѻýҕl>FDA Again Warns on Balloon Angioplasty for Neurologic Disordersѻýҕl> Says transvascular autonomic modulation is off-label and dangerous Mar 08, 2017
<ѻýҕl>Fatigue, Leg Dysfunction Predict Multiple Sclerosis Progressionѻýҕl> Both associated with subsequent conversion to secondary progressive MS Mar 01, 2017
<ѻýҕl>European MS Guidance Taking Shapeѻýҕl> ECTRIMS teases the first-ever MS drug guideline Sep 19, 2016
<ѻýҕl>Remyelinating Drug Flops in MSѻýҕl> Large placebo response, 'inverted U-shaped' dose-response in phase II trial Sep 18, 2016
<ѻýҕl>Registry Data: Lemtrada More Effective than Competing MS Txѻýҕl> Better than fingolimod or interferon; comparable to natalizumab Sep 17, 2016
<ѻýҕl>New Ampyra Trial Bolsters MS Efficacy Claimsѻýҕl> Walking ability, as reported by patients, significantly improved Sep 17, 2016
<ѻýҕl>Fluoxetine Flops as Progressive MS Therapyѻýҕl> Trial may have been underpowered to detect a benefit Sep 17, 2016
<ѻýҕl>Rituximab Bests MS Drugs in Swedish Registryѻýҕl> Rituximab offered drug survival advantage over fingolimod, natalizumab Sep 16, 2016